$EPIX
ESSA Pharma Inc

2022 Q1 Form 10-Q Financial Statement

#000155837022007960 Filed on May 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue $66.81K
YoY Change
Gross Profit -$66.81K
YoY Change
Gross Profit Margin
Selling, General & Admin $3.821M $4.620M
YoY Change -17.3% -6.67%
% of Gross Profit
Research & Development $7.649M $7.268M
YoY Change 5.24% 57.37%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $11.47M $11.88M
YoY Change -3.48% 24.17%
Operating Profit -$11.54M
YoY Change
Interest Expense $615.8K -$1.080M
YoY Change -157.01% -590.91%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$10.85M -$12.97M
YoY Change -16.28% 38.67%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$10.85M -$12.97M
YoY Change -16.28% 38.61%
Net Earnings / Revenue
Basic Earnings Per Share -$0.25 -$0.36
Diluted Earnings Per Share -$0.25 -$0.36
COMMON SHARES
Basic Shares Outstanding 44.03M 36.48M
Diluted Shares Outstanding 44.03M 36.48M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $181.0M $208.6M
YoY Change -13.22% 422.81%
Cash & Equivalents $86.24M $151.6M
Short-Term Investments $94.78M $57.00M
Other Short-Term Assets $1.064M $500.0K
YoY Change 112.89% -50.0%
Inventory
Prepaid Expenses $1.064M $492.0K
Receivables $19.25K $300.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $182.1M $209.4M
YoY Change -13.03% 408.21%
LONG-TERM ASSETS
Property, Plant & Equipment $247.4K $300.0K
YoY Change -17.54% 200.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $259.5K $300.0K
YoY Change -13.51% 0.0%
Total Long-Term Assets $506.8K $618.8K
YoY Change -18.09% 3.13%
TOTAL ASSETS
Total Short-Term Assets $182.1M $209.4M
Total Long-Term Assets $506.8K $618.8K
Total Assets $182.6M $210.0M
YoY Change -13.04% 402.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $756.6K $1.691M
YoY Change -55.25% 20.76%
Accrued Expenses $2.485M $1.352M
YoY Change 83.85% 1251.83%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.749M $3.180M
YoY Change 17.9% 111.98%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $145.3K $1.400M
YoY Change -89.62%
Total Long-Term Liabilities $145.3K $1.400M
YoY Change -89.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.749M $3.180M
Total Long-Term Liabilities $145.3K $1.400M
Total Liabilities $3.894M $4.593M
YoY Change -15.22% 206.2%
SHAREHOLDERS EQUITY
Retained Earnings -$137.7M -$100.5M
YoY Change 37.09%
Common Stock $278.0M $276.7M
YoY Change 0.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $178.7M $205.4M
YoY Change
Total Liabilities & Shareholders Equity $182.6M $210.0M
YoY Change -13.04% 402.39%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$10.85M -$12.97M
YoY Change -16.28% 38.61%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$8.385M -$7.580M
YoY Change 10.62% 26.76%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$26.63M -$35.00M
YoY Change -23.93%
Cash From Investing Activities -$26.63M -$35.00M
YoY Change -23.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 183.1K 141.6M
YoY Change -99.87% -1416500.0%
NET CHANGE
Cash From Operating Activities -8.385M -7.580M
Cash From Investing Activities -26.63M -35.00M
Cash From Financing Activities 183.1K 141.6M
Net Change In Cash -34.83M 99.06M
YoY Change -135.16% -1753.76%
FREE CASH FLOW
Cash From Operating Activities -$8.385M -$7.580M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44030480
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36484041
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44009903
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34896509
dei Entity Central Index Key
EntityCentralIndexKey
0001633932
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44059700
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43984346
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37410
dei Entity Registrant Name
EntityRegistrantName
ESSA Pharma Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A1
dei Entity Address Country
EntityAddressCountry
CA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1250703
dei Entity Address Address Line1
EntityAddressAddressLine1
Suite 720
dei Entity Address Address Line2
EntityAddressAddressLine2
999 West Broadway
dei Entity Address City Or Town
EntityAddressCityOrTown
Vancouver
dei Entity Address State Or Province
EntityAddressStateOrProvince
BC
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
V5Z 1K5
dei City Area Code
CityAreaCode
778
dei Local Phone Number
LocalPhoneNumber
331-0962
dei Security12b Title
Security12bTitle
Common Shares
dei Trading Symbol
TradingSymbol
EPIX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44059700
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86235830
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
137825024
CY2022Q1 us-gaap Short Term Investments
ShortTermInvestments
94782609
CY2021Q3 us-gaap Short Term Investments
ShortTermInvestments
57102159
CY2022Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
19254
CY2021Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
489012
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1064464
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2181882
CY2022Q1 us-gaap Assets Current
AssetsCurrent
182102157
CY2021Q3 us-gaap Assets Current
AssetsCurrent
197598077
CY2022Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
259455
CY2021Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
259455
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
247393
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
308286
CY2022Q1 us-gaap Assets
Assets
182609005
CY2021Q3 us-gaap Assets
Assets
198165818
CY2022Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3618508
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3808944
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
128366
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
120719
CY2022Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1929
CY2021Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3748803
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3929663
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
145268
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
210251
CY2022Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0
CY2021Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
20352
CY2022Q1 us-gaap Liabilities
Liabilities
3894071
CY2021Q3 us-gaap Liabilities
Liabilities
4160266
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44059700
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43984346
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
278029966
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
277415176
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
40538466
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
36442620
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2125210
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2076479
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-137728288
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117775765
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
178714934
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
194005552
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
182609005
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
198165818
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7649459
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7268257
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13669218
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11754029
CY2022Q1 epix Financing Costs
FinancingCosts
3526
CY2021Q1 epix Financing Costs
FinancingCosts
299
epix Financing Costs
FinancingCosts
7851
epix Financing Costs
FinancingCosts
1480
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3817370
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4615332
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6879540
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6824249
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
11470355
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
11883888
us-gaap Operating Expenses
OperatingExpenses
20556609
us-gaap Operating Expenses
OperatingExpenses
18579758
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
16259
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
7649
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
29428
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
14845
CY2022Q1 us-gaap Interest Income Deposits With Financial Institutions
InterestIncomeDepositsWithFinancialInstitutions
481751
CY2021Q1 us-gaap Interest Income Deposits With Financial Institutions
InterestIncomeDepositsWithFinancialInstitutions
39208
us-gaap Interest Income Deposits With Financial Institutions
InterestIncomeDepositsWithFinancialInstitutions
556335
us-gaap Interest Income Deposits With Financial Institutions
InterestIncomeDepositsWithFinancialInstitutions
74899
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
117741
CY2021Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1128216
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
18423
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1039086
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10854604
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12965247
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19952423
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19529100
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-35149
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-10854604
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-12965247
us-gaap Net Income Loss
NetIncomeLoss
-19952523
us-gaap Net Income Loss
NetIncomeLoss
-19493951
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-48731
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-48731
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10903335
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12965247
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20001254
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19493951
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44030480
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36484041
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44009903
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34896509
us-gaap Net Income Loss
NetIncomeLoss
-19952523
us-gaap Net Income Loss
NetIncomeLoss
-19493951
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
60893
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
55162
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-65060
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
us-gaap Accretion Expense
AccretionExpense
7410
us-gaap Accretion Expense
AccretionExpense
1480
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
18423
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1039086
epix Interest Income Operating Activities
InterestIncomeOperatingActivities
157464
epix Interest Income Operating Activities
InterestIncomeOperatingActivities
20106
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-19520
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
776985
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2663684
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12965247
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
205408071
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
194005552
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
55017103
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-23300
us-gaap Share Based Compensation
ShareBasedCompensation
4363444
us-gaap Share Based Compensation
ShareBasedCompensation
3868671
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-476062
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-19246
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1117418
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1108166
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-186188
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1883888
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14204791
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11515058
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
104817397
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
67028803
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
20000000
epix Interest From Short Term Investments
InterestFromShortTermInvestments
162789
epix Interest From Short Term Investments
InterestFromShortTermInvestments
13625
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-37625805
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35003478
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
149999985
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
9109462
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
319832
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
930686
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
249
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
27360
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
27369
epix Operating Lease Payments Financing Activities
OperatingLeasePaymentsFinancingActivities
64746
epix Operating Lease Payments Financing Activities
OperatingLeasePaymentsFinancingActivities
60575
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
282446
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
141788252
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-41044
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-28176
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-51589194
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
95241540
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
137825024
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56320763
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86235830
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
151562303
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
79243865
CY2020Q4 epix Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
149
CY2020Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
153701
CY2020Q4 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
27369
CY2020Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1204985
CY2020Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6528704
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
74101365
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
149999985
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
9168801
CY2021Q1 epix Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
100
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
178714934
CY2021Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
104324
CY2021Q4 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
27360
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2500091
CY2021Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9097919
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
187539408
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
215508
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1863353
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10903335
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.     NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Nature of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company was incorporated under the laws of the Province of British Columbia on January 6, 2009. The Company’s head office address is Suite 720 – 999 West Broadway, Vancouver, BC, V5Z 1K5. The registered and records office address is the 26<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Floor at 595 Burrard Street, Three Bentall Centre, Vancouver, BC, V7X 1L3. The Company is listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “EPIX”. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is focused on the development of small molecule drugs for the treatment of prostate cancer. The Company has acquired a license to certain patents (“NTD”) which were the joint property of the British Columbia Cancer Agency and the University of British Columbia. As of March 31, 2022, no products are in commercial production or use.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of the accompanying condensed consolidated interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as of the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liabilities, the valuation of equity instruments issued for services, income taxes and the product development and relocation grant. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these condensed consolidated interim financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both. Estimates and assumptions are reviewed quarterly.</p>
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
0
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
94655907
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
46502
CY2022Q1 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
173204
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
94782609
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
57026103
CY2021Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
76056
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
57102159
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
94800000
CY2021Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
57100000
CY2022Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
46502
CY2022Q1 us-gaap Prepaid Insurance
PrepaidInsurance
800780
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
1751052
CY2022Q1 epix Prepaid Preclinical And Clinical Expenses And Deposits
PrepaidPreclinicalAndClinicalExpensesAndDeposits
240513
CY2021Q3 epix Prepaid Preclinical And Clinical Expenses And Deposits
PrepaidPreclinicalAndClinicalExpensesAndDeposits
240513
CY2022Q1 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
23171
CY2021Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
190317
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1064464
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2181882
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2062441
CY2022Q1 us-gaap Accrued Vacation Current
AccruedVacationCurrent
376593
CY2021Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
320632
CY2022Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3618508
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3808944
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
756555
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1425871
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2485360
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
55162
epix Operating Lease Right Of Use Asset Addition
OperatingLeaseRightOfUseAssetAddition
341125
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
55162
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
341125
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
308286
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
60893
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
247393
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
59094
epix Operating Lease Liabilities Addition
OperatingLeaseLiabilitiesAddition
341125
epix Operating Lease Liabilities Accretion Expenses
OperatingLeaseLiabilitiesAccretionExpenses
1480
us-gaap Operating Lease Payments
OperatingLeasePayments
60574
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
341125
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
330970
epix Operating Lease Liabilities Accretion Expenses
OperatingLeaseLiabilitiesAccretionExpenses
7410
us-gaap Operating Lease Payments
OperatingLeasePayments
64746
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
273634
CY2022Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.050
CY2020Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
127376
CY2021 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
107023
CY2021Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
20353
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
18424
CY2022Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
1929
CY2022Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1929
CY2022Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5309584
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.42
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1889646
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.87
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
323610
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.68
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
72390
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.46
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6803230
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.20
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
170000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.85
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
72910
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.41
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
104584
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.18
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6795736
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.33
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3908576
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.14
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6795736
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M15D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
25258
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
170000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1714646
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1714646
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.85
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.85
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.77
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9272977
CY2020Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.73
epix Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
6038227
epix Class Of Warrant Or Right Weighted Average Exercise Price Warrants Exercised
ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised
-0.06
CY2022Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3234750
CY2022Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.84
CY2022Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3234750
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q1 epix Cash Canada Deposit Insurance Corporation Insured Amount
CashCanadaDepositInsuranceCorporationInsuredAmount
100000
CY2022Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2022Q1 epix Working Capital
WorkingCapital
178353354

Files In Submission

Name View Source Status
0001558370-22-007960-index-headers.html Edgar Link pending
0001558370-22-007960-index.html Edgar Link pending
0001558370-22-007960.txt Edgar Link pending
0001558370-22-007960-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20220331.xsd Edgar Link pending
tmb-20220331x10q.htm Edgar Link pending
tmb-20220331x10q001.jpg Edgar Link pending
tmb-20220331x10q_htm.xml Edgar Link completed
tmb-20220331xex31d1.htm Edgar Link pending
tmb-20220331xex31d2.htm Edgar Link pending
tmb-20220331xex32d1.htm Edgar Link pending
tmb-20220331_cal.xml Edgar Link unprocessable
tmb-20220331_def.xml Edgar Link unprocessable
tmb-20220331_lab.xml Edgar Link unprocessable
tmb-20220331_pre.xml Edgar Link unprocessable